Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF
  • Original article
  • Open access
  • Published:

Fetuin-A level in type 2 diabetic patients: relation to microvascular complications

The Egyptian Journal of Internal Medicine volume 30, pages 121–130 (2018)Cite this article

Abstract

Background

Fetuin-A is a hepatic secretory protein that binds to insulin receptors and inhibits insulin resistance (IR) kinase activity as well as IR autophosphorylation in vivo and in vitro.

Aim

This study aimed to investigate fetuin-A levels in patients with type 2 diabetes mellitus (T2DM) and their relation to microvascular complications.

Patients and methods

This descriptive study was conducted on 160 patients. Group 1 included (n=40) diabetic patients without microvascular complications, group 2 (n=40) included diabetic patients with nephropathy, group 3 (n=40) included diabetic patients with retinopathy, and group 4 represented (n=40) healthy control. Serum fetuin-A and insulin were measured by enzyme-linked immunosorbent assay. Glucose was measured, and homeostasis model assessment for IR (HOMA-IR) was estimated.

Results

Fetuin-A levels were significantly higher in all T2DM groups compared with controls. There was a significant positive correlation between fetuin-A, insulin, and HOMA-IR in all studied groups. There was a significant positive correlation between fetuin-A and some of metabolic syndrome criteria in all diabetic patients. There were high significant increases in the mean levels of fetuin-A, insulin, and HOMA-IR in the diabetic patients with nephropathy group than other groups. There was a nonsignificant increase in fetuin-A levels in diabetic patients with retinopathy than the diabetics without microvascular complications.

Conclusion

Fetuin-A may be used as a marker for microvascular complications in T2DM, especially the diabetic nephropathy. Antifetuin drugs may be invented to delay diabetic microvascular complications.

References

  1. Standards of Medical Care in Diabetes. Summary of revisions. Diabetes Care 2016; 39(Suppl 1):S4–S5.

    Google Scholar 

  2. International Diabetes Federation. Diabetes atlas. 7th ed. Brussels, Belgium: International Diabetes Federation; 2015.

    Google Scholar 

  3. Scirica BM. Use of biomarkers in predicting the onset, monitoring the progression, and risk stratification for patients with type 2 diabetes mellitus. Clin Chem 2017; 63:186–195.

    CAS  PubMed  Google Scholar 

  4. Kim HC, Greenland P, Rossouw JE, Manson JE, Cochrane BB, Lasser NL, et al. Multimarker prediction of coronary heart disease risk: The Women’s Health Initiative. J Am Coll Cardiol 2010; 55:2080–2091.

    CAS  PubMed  Google Scholar 

  5. Maruo S, Mori K, Motoyama K, Nakamura M, Kawarabayashi R, Kakutani Y, et al. Correlation analysis of monocyte subsets and insulin resistance considering fetuin-A involvement in patients with type 2 diabetes. Clin Transl Med 2018; 7: 9.

    PubMed  PubMed Central  Google Scholar 

  6. Denecke B, Graber S, Schafer C, Heiss A, Woltje M, Jahnen-Dechent W. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem J 2003; 376:135–145.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Schafer C, Heiss A, Schwarz A, Westenfleld R, Ketteler M, Floege J, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357–366.

    PubMed  PubMed Central  Google Scholar 

  8. Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Haring HU, Stefan N. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS ONE 2008; 3:e1765.

  9. Srinivas PR, Wagner AS, Reddy LV, Deutsch DD, Leon MA, Goustin AS, Grunberger G. Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol 1993; 7:1445–1455.

    CAS  PubMed  Google Scholar 

  10. Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA. Association between human fetuin-A and the metabolic syndrome. Data from the Heart and Soul Study. Circulation 2006; 113:1760–1767.

    CAS  PubMed  Google Scholar 

  11. Ix JH, Wassel CL, Kanaya AM, Vittinghoff E, Johnson KC, Koster A, et al. Fetuin-A and incident type 2 diabetes mellitus in older persons. JAMA 2008; 300: 182–188.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361:827–833.

    CAS  PubMed  Google Scholar 

  13. Weikert C, Stefan N, Schulze MB, Pischon T, Berger K, Joost HG, et al. Plasma fetuin-A levels and the risk of myocardial infarction and ischemic stroke. Circulation 2008; 118:2555–2562.

    CAS  PubMed  Google Scholar 

  14. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2009; 32(Suppl 1):S13–S61.

    PubMed Central  Google Scholar 

  15. Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. Indices of relative weight and obesity. J Chronic Dis 1972; 25:329–343.

    CAS  PubMed  Google Scholar 

  16. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126:840–848.

    CAS  PubMed  Google Scholar 

  17. Flegg HM. An investigation of serum cholesterol by an enzymatic method. Ann Clin Biochem 1973; 10:79.

    CAS  Google Scholar 

  18. Buccolo G, David H. Quantitative determination of serum triglycerides by use of enzymes. Clin Chem 1973; 19:467–482.

    Google Scholar 

  19. Finley PR. Determination of high density lipoprotein (HDL) cholesterol in serum or plasma. Clin Chem 1978; 24:931.

    CAS  PubMed  Google Scholar 

  20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499–502.

    CAS  PubMed  Google Scholar 

  21. Bartels H, Böhmer M, Heierli C. Serum creatinine determination without protein precipitation. Clin Chim Acta 1972; 37:193–197.

    CAS  PubMed  Google Scholar 

  22. Rose CFM. The estimation of urea by urease methods in fluoride blood. Br J Exp Pathol 1933; 14:339–342.

    CAS  PubMed Central  Google Scholar 

  23. Varley H, Gowenlock AH. Collection of specimens and some general techniques. Practical clinical biochemistry: general topics and commoner tests. 5th ed. London: Butterworth-Heinemann Ltd; 1980. 379–380

    Google Scholar 

  24. Stevens LA, Levey AS. Current status and future perspectives for CKD testing. Am J Kidney Dis 2009; 53: S17–S26.

    PubMed  Google Scholar 

  25. Vionnet N, Hani EH, Dupont S, Gallina S, Francke S, Dotte S, et al. Genome wide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2- diabetes locus on chromosome 1q21–q24. Am J Hum Genet 2000; 67:1470–1480.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Lorenzo C, Wagenknecht LE, D’Agostino RB Jr, Rewers MJ, Karter AG, Haffner SM. Insulin resistance, β-cell dysfunction, and conversion to type 2 diabetes in a multiethnic population. Diabetes Care 2010; 33:67–72.

    CAS  PubMed  Google Scholar 

  27. Guo VY, Cao B, Cai C, Cheng KK, Cheung BMY. Fetuin-A levels and risk of type 2 diabetes mellitus: a systematic review and meta-analysis. Acta Diabetol 2018; 55:87–98.

    CAS  PubMed  Google Scholar 

  28. Sujana C, Huth C, Zierer A, Meesters S, Sudduth-Klinger J,Koenig W, et al. Association of fetuin-A with incident type 2 diabetes: results from the MONICA/KORA Augsburg study and a systematic meta-analysis. Eur J Endocrinol 2018; 178:389–398.

    CAS  PubMed  Google Scholar 

  29. Pinnaduwage L, Ye C, Hanley AJ, Connelly PW, Sermer M, Zinman B, Retnakaran R. Changes over time in hepatic markers predict changes in insulin sensitivity, beta-cell function and glycemia. J Clin Endocrinol Metabol 2018; 103:2018–00306.

    Google Scholar 

  30. Roshanzamir F, Miraghajani M, Rouhani MH, Mansourian M, Ghiasvand R, Safavi SM. The association between circulating fetuin-A levels and type 2 diabetes mellitus risk: systematic review and meta-analysis of observational studies. J Endocrinol Invest 2107; 41:33–47.

    Google Scholar 

  31. Yin L, Cai W-J, Zhu L-Y, Li J, Su X-H, Wang X-L, et al. Association of plasma Fetuin-A and clinical characteristics in patients with new-onset type 2 diabetes mellitus. Int J Clin Exp Med 2015; 8:991–999.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Ou HY, Lu FH, Wu HT, Hung HC, Wu JS, Yang YC, Chang CJ. Both diabetes and fetuin-A are independently associated with increased risk of arterial stiffness. Clin Chim Acta 2015; 445:133–138.

    CAS  PubMed  Google Scholar 

  33. Iyidir OT, Degertekin CK, Yilmaz BA, Altinova AE, Toruner FB, Bozkurt N, et al. Serum levels of fetuin A are increased in women with gestational diabetes mellitus. Arch Gynecol Obstet 2015; 291:933–937.

    CAS  PubMed  Google Scholar 

  34. Song A, Xu M, Bi Y, Xu Y, Huang Y, Li M, et al. Serum fetuin-A associates with type 2 diabetes and insulin resistance in Chinese adults. PLoS ONE 2011; 6:e19228.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, Häring HU, Schulze MB. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 2008; 57:2762–2767.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Takata H, Ikeda Y, Suehiro T, Ishibashi A, Inoue M, Kumon Y, Terada Y. High glucose induces transactivation of the alpha2-HS glycoprotein gene through the ERK1/2 signaling pathway. J Atheroscler Thromb 2009; 16:448–456.

    CAS  PubMed  Google Scholar 

  37. Ishibashi A, Ikeda Y, Ohguro T, Kumon Y, Yamanaka S, Takata H, et al. Serum fetuin-A is an indeoendent marker of insulin resistance in Japanese men. J Atheroscler Thromb 2010; 17:925–933.

    CAS  PubMed  Google Scholar 

  38. Kröger J, Meidtner K, Stefan N, Guevara M, Kerrison ND, Ardanaz E, et al. Circulating fetuin-a and risk of type 2 diabetes: a mendelian randomization analysis. Diabetes 2018; [Epub ahead of print]

  39. Eleftheriadou I, Grigoropoulou P, Kokkinos A, Mourouzis I, Perrea D, Katsilambros N, et al. Association of plasma fetuin-a levels with peripheral arterial disease and lower extremity arterial calcification in subjects with type 2 diabetes mellitus. J Diabetes Complications 2017; 31:599–604.

    PubMed  Google Scholar 

  40. Eraso LH, Ginwala N, Qasim AN, Mehta NN, Dlugash R, Kapoor S, et al. Association of lower plasma fetuin-a levels with peripheral arterial disease in type 2 diabetes. Diabetes Care 2010; 33:408–410.

    CAS  PubMed  Google Scholar 

  41. Roos M, Oikonomou D, von Eynatten M, Luppa PB, Heemann U, Lutz J, et al. Associations of fetuin-A levels with vascular disease in type 2 diabetes patients with early diabetic nephropathy. Cardiovasc Diabetol 2010; 9:48.

    PubMed  PubMed Central  Google Scholar 

  42. Mori K, Emoto M, Yokoyama H, Araki T, Teramura M, Koyama H, et al. Association of serum fetuin-A with insulin resistance in type 2 diabetic and non-diabetic subjects. Diabetes Care 2006; 29:468.

    PubMed  Google Scholar 

  43. Yilmaz MI, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, et al. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant 2008; 23:1621–1627.

    CAS  PubMed  Google Scholar 

  44. Zhou ZW, Ju HX, Sun MZ, Chen HM, Fu QP, Jiang DM. Serum fetuin-A levels in obese and non-obese subjects with and without type 2 diabetes mellitus. Clin Chim Acta 2018; 476:98–102.

    CAS  PubMed  Google Scholar 

  45. Gunduz FO, Yildirmak ST, Temizel M, Faki Y, Cakmak M, Durmuscan M, Sezgin F. Serum visfatin and fetuin-a levels and glycemic control in patients with obese type 2 diabetes mellitus. Diabetes Metab J 2011; 35:523–528.

    PubMed  PubMed Central  Google Scholar 

  46. Reinehr T, Karges B, Meissner T, Wiegand S, Fritsch M, Holl RW, Woelfle J. Fibroblast growth factor 21 and fetuin-a in obese adolescents with and without type 2 diabetes. J Clin Endocrinol Metab 2015; 100:3004–3010.

    CAS  PubMed  Google Scholar 

  47. Stępień M, Wlazeł RN, Paradowski M, Banach M, Rysz M, Misztal M, Rysz J. Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo- and hypertensive patients – pilot study. Arch Med Sci 2012; 8:431–436.

    PubMed  PubMed Central  Google Scholar 

  48. Lewis GF, Uffe lman KD, Szeto LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very lowdensity lipoprotein production in humans. J Clin Invest 1995; 95:158–166.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Xu Y, Xu M, Bi Y, Song A, Huang Y, Liu Y, et al. Serum fetuin-A is correlated with metabolic syndrome in middle-aged and elderly Chinese. Atherosclerosis 2011; 216:180–186.

    CAS  PubMed  Google Scholar 

  50. Yang J, Maika S, Craddock L, King JA, Liu ZM. Chronic activation of AMP-activated protein kinase-alpha1 in liver leads to decreased adiposity in mice. Biochem Biophys Res Commun 2008; 370:248–253.

    CAS  PubMed  Google Scholar 

  51. Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118:1645–1656.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Inoue K, Wada J, Eguchi J, Nakatsuka A, Teshigawara S, Murakami K, et al. Urinary fetuin-A is a novel marker for diabetic nephropathy in type 2 diabetes identified by lectin microarray. PLoS ONE 2013; 8:e77118.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Mehrotra R, Westenfeld R, Christenson P, Budoff M, Ipp E, Takasu J, et al. Serum fetuin A in non-dialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int 2005; 67:1070–1077.

    CAS  PubMed  Google Scholar 

  54. Yilmaz A, Yilmaz T,, Gunay M. Elevated serum fetuin-A levels are associated with grades of retinopathy in type 2 diabetic patients. Int Ophthalmol 2017; 37:113–117.

    Google Scholar 

  55. Zhao C, Hou J, Wang S, Jiang R. Relation of serum and vitreous concentrations of fetuin-a with diabetic retinopathy. Med Sci Monit 2015; 21:1839–1842.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt

    Nehal H. Al-Said

  2. Department of Medical Biochemistry, Faculty of Medicine, Cairo University, Cairo, Egypt

    Fatma M. Taha

  3. Department of Medical Biochemistry, Faculty of Medicine, Beni-Suef University, 6 El Maghraby Street, Elwasta, Beni Suef, 51162, Egypt

    Ghada M. Abdel-Aziz & Marwa S. Abdel-Tawab PhD of Medical Biochemistry and Molecular Biology

Authors
  1. Nehal H. Al-Said
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fatma M. Taha
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ghada M. Abdel-Aziz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marwa S. Abdel-Tawab PhD of Medical Biochemistry and Molecular Biology
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marwa S. Abdel-Tawab PhD of Medical Biochemistry and Molecular Biology.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Al-Said, N.H., Taha, F.M., Abdel-Aziz, G.M. et al. Fetuin-A level in type 2 diabetic patients: relation to microvascular complications. Egypt J Intern Med 30, 121–130 (2018). https://doi.org/10.4103/ejim.ejim_24_18

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_24_18

Keywords